Does rifabutin interact with Eliquis (apixaban)?

Rifabutin Significantly Interacts with Eliquis (Apixaban) and Should Be Avoided

Avoid concomitant use of rifabutin with Eliquis (apixaban) due to the risk of reduced anticoagulant efficacy and potential thrombotic events. Rifabutin is a moderate-to-strong inducer of both CYP3A4 and P-glycoprotein (P-gp), the two primary pathways responsible for apixaban metabolism and elimination 1, 2.

Mechanism of Interaction

Apixaban is metabolized via CYP3A4 and is a substrate of P-gp transporters 1, 2. Rifabutin induces both of these pathways, leading to:

• Decreased apixaban plasma concentrations through enhanced metabolism and increased elimination 2, 3
• Reduced anticoagulant effect with potential loss of therapeutic efficacy 1, 4
• Increased risk of stroke and thromboembolic events due to subtherapeutic drug levels 2

The FDA label for Eliquis explicitly states: "Avoid concomitant use of ELIQUIS with combined P-gp and strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's wort) because such drugs will decrease exposure to apixaban" 2. While rifabutin is not specifically named in this list, it functions as a combined P-gp and CYP3A4 inducer 3, 5, 6.

Clinical Evidence

A recent case report documented breakthrough deep vein thrombosis (DVT) in a patient taking edoxaban with rifabutin, demonstrating that rifamycin interactions extend beyond rifampin 7. This case highlights that even "moderate" CYP3A4 inducers like rifabutin can cause clinically significant DOAC failure 7.

The 2024 ACC/AHA/ACCP/HRS guidelines emphasize that apixaban requires dose reduction when combined with strong dual P-gp/CYP3A4 inhibitors, and conversely, the drug interaction management table explicitly states to "avoid use" with P-gp/CYP3A4 inducers 1.

Comparison with Other Rifamycins

• Rifampin causes a 50% decrease in rivaroxaban AUC and is contraindicated with all DOACs 8
• Rifabutin has less severe induction effects than rifampin but still significantly reduces DOAC levels 3, 5, 9
• The 2018 European Heart Rhythm Association guide states that "strong inducers of P-gp and/or CYP3A4 (such as rifampicin, carbamazepine, etc.) will markedly reduce NOAC plasma levels; such combinations should be avoided or used with great caution and surveillance" 4

Clinical Recommendations

If tuberculosis or mycobacterial treatment is required in a patient on apixaban:

1. Switch to warfarin as the preferred anticoagulant, which can be monitored via INR and dose-adjusted accordingly 10, 7
2. Do not attempt dose adjustment of apixaban - there is no validated dosing regimen for apixaban when combined with rifabutin 1, 2
3. If rifabutin must be used temporarily, consider bridging with low-molecular-weight heparin during the overlap period, though this adds bleeding risk 10

Important Caveats

• Unlike some drug interactions where apixaban dose reduction is recommended (e.g., with strong dual inhibitors), there is no safe dose adjustment strategy for apixaban when combined with inducers 1, 2
• The interaction persists for approximately 2 weeks after rifabutin discontinuation due to the time required for enzyme de-induction 8, 10
• Therapeutic drug monitoring of apixaban is not routinely available or validated for clinical decision-making in this context 11, 12